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Résumé 
Il s'agit de comparer in vivo la sécurité et l'efficacité d'un implant en polyméthylméthacrylate (PMMA) 
avec un implant standard en collagène dans la sclérectomie profonde (SP) sur une durée de six mois. La 
population étudiée comprend vingt lapins, chaque lapin étant randomisé pour une SP avec implant en 
PMMA dans un œil et implant de collagène dans l'autre œil. 
Plusieurs éléments ont été pris en compte dans la comparaison : 
la mesure de la pression intraoculaire 
l'évolution de l'espace de drainage intrascléral et de la bulle de filtration sous-conjonctivale, suivie 
par ultrasonographie biomicroscopique (UBM) 
la croissance de nouveaux vaisseaux de drainage sous-conjonctivaux, croissance quantifiée par 
angiographie du segment antérieur à la fluorescéine combinée au vert d'indocyanine 
la facilité à l'écoulement de l'humeur aqueuse (C), mesurée à six mois par cannulation-perfusion de 
la chambre antérieur 
la sclère au site de SP, histologiquement comparée à la sclère native opposée à 180°, également à six 
mois 
La pression intraoculaire moyenne préopératoire à une, quatre, douze et 24 semaines postopératoires est 
comparable dans les deux groupes (P>O. l ). L'UBM montre une régression légèrement plus rapide 
(statistiquement non significative) de la bulle de filtration sous-conjonctivale et la persistance d'un espace 
de drainage intrascléral dans le groupe PMMA (P>0.05). De nouveaux vaisseaux de drainage sont 
observés à un mois de la chirurgie ; à six mois, ces vaisseaux sont plus nombreux dans le groupe PMMA, 
tant sur l'analyse angiographique que sur l'analyse histologique (P>0.05). La facilité moyenne à 
l'écoulement de l'humeur aqueuse est significativement plus élevées à six mois dans les deux groupes par 
rapport aux valeurs préopératoires (P>0.05), sans qu'il n'y ait de différence entre les deux implants (0.24 
± 0.06µ1/min/mmHg [PMMA] et 0.23 ± 0.07 µl/min/mmHg [implant en collagène]) (P = 0.39). 
Cette étude a pu démontrer que la sclérectomie profonde avec implant en collagène ou en PMMA donne 
des résultats similaires en terme de diminution de l'IOP et d'augmentation de la facilité à l'écoulement de 
l'humeur aqueuse, sans différence sur le plan des réactions inflammatoires post-intervention. 
( 
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ABSTRACT 
Background: Study in vivo characteristics of a poly-
methylmethacrylate (PMMA) implant compared to 
the standard cylindrical collagen implant for deep 
sclerectomy (D S). 
Design: Six-month comparative study. 
Samples: Twenty eyes of ten rabbits. 
Methods: Eyes were randomized to have DS with 
PMMA implant in one eye and collagen implant in 
the opposite eye. The growth of the new subcon-
junctival drainage vessels was assessed by combined 
fluorescein and indocyanin green anterior segment 
angiography; intrascleral and subconjunctival blebs 
were imaged by ultrasound biomicroscopy (UBM). 
At six months, outflow facility (C) was measured by 
anterior chamber perfusion and portions of one side 
of the D S were compared to portions on the 180° 
opposite side and native sclera on histology. 
Results: The mean IOP preoperatively and at one, 
four, twelve, and twenty-four weeks was compa-
rable in both groups (P> 0.1). UBM showed a statis-
tically insignificant quicker regression of the 
subconjunctival bleb as well as a durable intrascleral 
lake in the PMMA group (P> 0.05). New drainage 
vessels were initially observed one month after 
surgery; they were more numerous in the PMMA 
group on angiographie and histological findings at 6 
months (P < 0.05). The mean C increased signifi-
cantly after surgery compared to preoperative values 
(P < 0.05) and no difference was observed between 
the implants (0.24 ± 0.06 µl/min/mmHg [PMMA] 
and 0.23 ± 0.07 µl/min/mmHg [collagen implant]) 
(P= 0.39). 
Conclusions: Deep sclerectomy performed with 
PMMA or collagen implants showed similar IOP low-
ering effects, outflow facility increase, and degree of 
inflammatory reaction. 
Key words: collagen implant, deep sc/erectomy, glau-
coma, PMMA implant, rabbits. 
INTRODUCTION 
Deep sclerectomy (DS) is a non-perforating filtration 
procedure used for the surgical treatment of open-
angle glaucoma. 1 Intrascleral space maintaining 
devices are used to diminish the risk of scleral fibro-
sis and to enhance the flow from the anterior 
chamber to the subconjunctival space by avoiding 
the collapse of the newly created intrascleral space.2 
The implants may differ in material, size, shape, 
design, consistency, water content and rate of 
absorption. 
An X-shaped implant made of non-absorbable 
polymethylmethacrylate (PMMA), was designed by 
one of the study authors (AM) to enhance the intras-
cleral outflow. PMMA is a well-tolerated prosthetic 
material used for more than 50 years in ophthalmic 
surgery, mostly in cataract surgery.3 In addition, the 
PMMA implant is less costly than the collagen 
implant. Our group has previously shown that the 
X-shaped PMMA implant has similar success and 
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a 
Figure 1. Light microscopy views of: (a) non-absorbable 
X-shaped polymethylmethacrylate implant; (b) cylindrical 
absorbable collagen implant. 
complication rates in patients with uncontrolled 
open-angle glaucoma.4 To enable careful study of in 
vivo changes related to the PMMA implant, we 
designed a laboratory study using a rabbit model of 
glaucoma surgery to document the angiographie, 
ultrasound biomicroscopy (UBM) and outflow facil-
ity of the PMMA implant compared with the cylin-
drical collagen implant. 5 
METHODS 
The glaucoma space maintainers 
The cross-shaped PMMA (HOMDEC SA, Belmont, 
Switzerland) was developed at the glaucoma unit of 
the Jules Gonin Eye Hospital, University of Lau-
sanne, Switzerland. It is a rigid, non-absorbable 
implant. The cross-shaped drainage device measures 
4.0 x 4.0 mm, with a total length of arm of 5.4 mm 
and has a thickness of 0.5 mm (Fig. la). The corn-
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mercially available cylindrical collagen implant 
drainage device (Aqua-Flow, Staar Surgical AG, 
Nidau, Switzerland) measures 1.0 x 1.0 x 4.4 mm 
and is placed radially in the centre of the DS dissec-
tion and secured with a single 10-0 nylon suture 
to the thin remuant scierai layer, posterior to 
Schlemm's canal (Fig. lb). The implant is processed 
from lyophilized porcine scierai collagen that has 
been sterilized by radiation. The collagen implant 
swells with aqueous and tissue fluid once it is placed 
in the eye, is absorbed within 6-9 months after 
surgery and then replaced by a younger, more porous 
collagen meshwork that sustains the exit pathway. 
Study protocol 
The entire procedure, care and treatment of the 
rabbits were in accordance with the Cantonal Veteri-
nary Service of Lausanne, Switzerland, and the 
ARVO statement for the use of animais in oph-
thalmic research (http://www.arvo.org/ AboutArvo/ 
animalst.asp#Recommended %20References). 
All experiments were performed under general 
anaesthesia by an intramuscular injection of a 
37.5 mg/kg ketamine and a 5.0 mg/kg xylazine 
solution. After appropriate acclimatizing, 10 pig-
mented female rabbits (2.0-3.0 kg) underwent DS 
on both eyes by the same experienced surgeon (SR). 
A superior rectus muscle suture was placed. The 
conjunctiva and Tenon's capsule were opened in the 
upper fornix, and the sciera was exposed. A limbus-
based 5 x 5 mm scierai flap, with a thickness of one-
third of the sciera (300 µm), was created. To be able 
to reach the Descemet's membrane later in the dis-
section, the superficial scierai flap had to be eut first 
anteriorly into the clear cornea. A second deep scierai 
flap measuring 4 x 4 mm was then dissected. The 
horizontal dissection was performed starting poste-
riorly and moving anteriorly using a crescent blade. 
Near the limbus the Schlemm's canal was automati-
cally unroofed. The dissection was continued anteri-
orly using a blunt spatula or a sponge to find the 
natural cleavage plan between the Descemet's mem-
brane and the corneal stroma. When the Descemet's 
membrane had been exposed for 1 mm, the second 
scierai flap was excised. One eye randomly received 
a cross-shaped PMMA implant; the other one 
received a cylindrical collagen implant. After putting 
the implant in place, the superficial scierai flap was 
repositioned over the implant and secured with two 
single 10-0 nylon sutures; the knots were buried 
inside the flap. The conjunctiva and Tenon's capsule 
were then closed with a running 8-0 polyglactin 
(Vicryl) suture. 
The intraocular pressure (IOP) (the mean of five 
consecutive readings) was recorded weekly during 
the first month and then every second week thereaf-
© 2010 The Authors 
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ter for 5 months. IOP was measured by the same 
persan (AC) who was unaware of which implant 
had been placed in which eye of each rabbit. This 
was to avoid interpersonal differences using a 
TONO-Pen-XL tonometer (Mentor, Norwell, MA, 
USA).6 Recordings were performed between 11:00 
AM and 3:00 PM to limit the effects of diurnal 
variation. The presence of an intrascleral lal<:e and a 
subconjunctival blebs at 1, 3 and 6 months after DS 
was assessed by UBM by the main investigator (AC). 
The images shown in this article were obtained with 
a human setting commercial UBM (Humphrey 
Instruments, Inc., San Leandro, CA, USA) and a 
standard 50 MHz transducer. A non-disposable hard 
plastic eye cup measuring 18 mm diameter was 
inserted between the lids, and methylcellulose was 
the coupling agent. Multiple cross-sections of images 
were taken of the anterior segment and the bleb, 
from the limbus to its posterior extent. The image 
that displays maximum bleb height was used for 
measurement. The bleb height was measured with 
calipers provided in the system software. The growth 
of new intrascleral drainage vessels was assessed by 
simultaneous indocyanin green and fluorescein ante-
rior segment angiography 1, 3 and 6 months after 
surgery as we described it previously.7 After general 
anaesthesia, 0.2 mL of a solution of 0.1 mL (1 mg/ 
mL) of fluoresceine and 0.1 mL (1 mg/mL) of 
indocyanin green were injected into the interior 
chamber although limbal paracenthesis. Several 
sequences pictures of the surgical site were taken 
with a digital can1era (TRC50IA, Nidek, Tokyo, 
Japan). Following the procedures eyes were treated 
for seven days with a daily drop of Dexamethasone 
and Chloramphenicol (Spersadex C, Ciba Vision, 
Bülach, Switzerland). The number of drainage 
vessels ( encompassed in an area delineated by a 
virtual line drawn 2 mm parallel to the limbus and 
extending from the lateral edge of the superior rectus 
muscle down to the upper edge of lateral rectus 
muscle) was counted. 
Six months after surgery, outflow facility ( C) was 
measured using the technique of anterior chamber 
perfusion under constant pressure.B-1° Under micro-
scopie control, the eyes were pressurized with a 
needle-guided silicon catheter introduced through 
the corneal limbus into the anterior chamber, 180° 
away from the surgical site. The catheter was con-
nected via a polyethylene tubing to a micro-syringe 
pump (type SP 200i, WPI, Sarasota, FL, USA) allow-
ing various flow rate ranging from 0.2 mL/h to 
426 mL/h. The catheter-syringe unit was then con-
nected to a water manometer and an electronic 
pressure transducer (WPI, Sarasota, FL, USA). Pres-
sure measurements were monitored by a pressure 
monitor (Ape BP-1, WPI, Sarasota, FL, USA) and 
printed on a chart recorder (Type 1200 E, Linseis 
© 2010 The Authors 
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GmbH, Selb, Germany). The IOP could be increased 
or lowered by adjusting the height of the water 
manometer. The pressure system was adjusted at the 
lowest pressure at which a flow was detectable. IOP 
was then increased by 10 mmHg increments to a 
maximum 40 mmHg. At each pressure level, the 
infusion flow was adjusted to maintain the IOP con-
stant, which corresponded to the outflow of the eye 
minus the aqueous produced by the ciliary body. The 
infusion flows were then plotted against IOP and a 
regression line was computed. The slope of the curve 
represents the outflow facility. The outflow facility 
( C) was calculated using the Goldmann equation: 
C=!'!..I/MOP 
!'!..I = (I2 - Il), where Il and I2 are successive 
inflow rates (µL/min) 
!'!..IOP = (P2 - Pl), where Pl and P2 represent 
IOP at Il and J2, respectively (mmHg) 
The mean outflow facility of each implant group 
was then compared with the mean physiological 
outflow facility of about 0.15 ± 0.02 µL/min/ 
mmHg. 10 At the end of the outflow facility measure-
ment, a 50 mg/mL cationic ferritin solution (horse 
spleen ferritin, MW= 800 000, Biochemica, Fluka 
Chemie, Buchs, Switzerland) was injected through 
the catheter into the anterior chamber. While main-
taining the IOP at about 40 mmHg, the ferritin was 
allowed to diffuse into the trabecular meshwork and 
the new drainage vessels for 15 min. The eyes were 
then immediately enucleated after an intracardiac 
injection of a 65 mg/mL sodium pentobarbital solu-
tion and fixed in a 4% formaldehyde solution. His-
tological sections of the entire eye (radial eut) were 
performed and stained using haematoxylin-eosin 
(HE) and Prussian blue dye, which reacts with 
ferritin-marked tissues. The aqueous drainages 
vessels were identified by their blue colour caused 
by the reaction between ferritin and Prussian blue. 10 
Light microscopy at an original magnification xlOO 
was used to observe the mean number of new 
aqueous drainage vessels in the sclera, the inflam-
matory response and scarring process around the 
implant. The mean number of drainage vessel 
from five consecutive sections at the surgical site was 
compared with five consecutive sections on non-
operated region 180° opposite from surgery site. 
Statistical analysis 
The data are presented as the mean ± standard 
deviation (SD). Comparisons of the means were per-
fonned using the Wilcoxon rank sum test between 
eye and Kruskal-Walllis test for different time point 
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measurement. A difference was considered statisti-
cally significant when P < 0.05. 
RESULTS 
No perforation of the trabeculo-Descemet's mem-
brane (TDM) occurred in any of the surgical 
procedures. All experiments were well tolerated by 
each animal throughout the entire study. None of the 
eyes presented clinically significant postoperative 
anterior chamber inflammation. One eye developed a 
small anterior chamber fibrin filament (inferior to 
1 mm), which resolved spontaneously following the 
angiography at the third month. All corneas stayed 
clear, there was no case of corneal oedema, and no 
endophthalmitis was observed. Comprehensive 
results are presented in Tables 1-4. 
lntraocular pressure 
The mean IOP follow up is depicted in Figure 2b. 
For the PMMA implant group, the mean IOP signifi-
cantly decreased from a preoperative value of 
13.3 ± 0.8 mmHg to a postoperative value of 9.3 ± 
1.5 mmHg at 1 week (reduction of 4.0 ± 1.4 mmHg 
[30.0%]; P < 0.05), 9.6 ± 0.5 mmHg at 1 month 
(P < 0.05), ll.7 ± 1.2 at 3 months (P < 0.05) and 
12.1 ± 0.9 mmHg at 6 months (reduction of 1.2 ± 
0.8 mmHg or 9.0%; P < 0.05). In the cylindrical col-
lagen implant group, the mean IOP significantly 
changed from a preoperative value of 13.4 ± 
0.8 mmHg to a postoperative value of 8.8 ± 
0.8 mmHg 1 week after surgery, thus representing a 
reduction of 4.6 ± 0.8 mmHg (34, 3%) (P < 0.05). At 
1 month, the postoperative IOP was 9.5 ± 0.5 mmHg 
(P < 0.05), at 3 months 11.7 ± 1.1 mmHg (P < 0.05) 
and at 6 months 12.0 ± 0.9 mmHg, showing a reduc-
tion of 1.4 ± 0.9 mmHg (10.4%) (P < 0.05). The 
Table 1. Time-course changes in IOP reduction from baseline IOP 
IOP reductions (mmHg and%) from baseline IOP 
Collagen implant 
PMMA implant 
Wilcoxon rank sum test (P) 
1 week 
4.6 ± 0.8 
(34.3%) 
4.0 ± 1.4 
(30.0%) 
0.13 
IOP, intraocular pressure; PMMA, polymethylmethacrylate. 
Table 2. Maximum subconjunctival bleb's height over time (cm) 
Subconjunctival thickness (cm) ± standard deviation 
Codreanu et al. 
differences in the IOP drop at 1 week, l, 3 and 
6 months after surgery were not statistically signifi-
cant between the two groups (Table 1). 
UBM analysis 
The non-resorbable PMMA implants were easily 
identified postoperatively and during the entire 
follow up (Fig. 2). No evidences of structural modi-
fication or displacement of the implant were noted. 
The size of the collagen implants decreased progres-
sively over time. After 6 months, the collagen 
implants were no longer visible. Instead, the 
degraded implants left a visible void in the intras-
cleral space. Subconjunctival filtration blebs were 
present at the surgical site in all eyes of both groups 
at l, 3 and 6 months postoperatively. There was a 
tendency for faster regression of the subconjunctival 
bleb's height over time in the PMMA group (P = NS) 
(Table 2). TDM was well delineated between the 
anterior chamber and the intrascleral space. The 
intrascleral space, between the posterior part of the 
trabeculum and the anterior portion of the implant, 
was noticeable in both groups at all times. A supra-
choroidal effusion was observed under the sclerec-
tomy site in five eyes (50%) with PMMA implant 
and in three eyes (30%) with the collagen device 
(P < 0.05). However, no case of retinal detachment 
was observed. 
Angiography 
One month after surgery, collagen implants were 
seen as a hypofluorescent mass within the scleral 
bed. At 3 months, the implants were no longer 
identifiable following complete biodegradation. 
The non-resorbable PMMA implants remained 
plainly visible over time, their contour being well 
1 month 
1 month 
3.9 ± 0.5 
(29.1%) 
3.7 ± 0.5 
(27.8%) 
0.19 
3 months 
1.7 ± 1.0 
(12.6%) 
1.6 ± 1.2 
(12%) 
0.25 
3 months 
6 months 
1.4 ± 0.9 
(10.4%) 
1.2 ± 0.8 
(9.0%) 
0.14 
6 months 
Collagen implant 
Polymethylmethacrylate implant 
Wilcoxon rank sum test (P) 
0.20 ± 0.06 
0.22 ± 0.05 
0.57 
0.19±0.09 
0.18±0.05 
0.69 
0.20 ± 0.06 
0.15 ± 0.06 
0.09 
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Figure 2. Ultrasound biomicroscopy images showing: (a) 
transversal view of the X-shaped polymethylmethacrylate 
implant (i); (b) radial view of subconjunctival bleb (sb). 
delineated by tluorescein. The modified aqueous 
drainage pathway was easily visualized. The filtra-
tion bleb and the surrounding new aqueous subcon-
junctival draining vessels were clearly visible on 
angiography 1 month after surgery for both types of 
implant. A progressive growth of these vessels 
around the filtration site was clearly observed at 3 
and 6 months (Fig. 3). In both groups, marked pro-
liferation of new drainage vessels was observed 
between the first and the third postoperative month. 
However, no statistical differences were observed 
between the two groups (Table 3). The angiographie 
results were interpreted, and any indication of which 
implant had been used were masked. 
© 2010 The Authors 
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Outflow facility 
Six months after surgery, the mean outtlow facility 
was 0.24 ± 0.06 µL/min/mmHg for the PMMA and 
0.23 ± 0.07 µL/min/mmHg for the collagen group. 
The mean outtlow facility for both groups signifi-
cantly dropped from the physiological value (P < 
0.05). The differences in the mean outtlow facility 
drop after surgery were not statistically significant 
between the two groups (P = 0.32). 
Histological examinations 
In both groups, light microscopy at 6 months after 
surgery revealed presence of more drainage vessels 
(Figure 4a and b) in the sclera adjacent to the dissec-
tions site compare with the opposite limbal sclera. In 
the PMMA group, there were 3.7 ± 0.8 new drain-
age vessels per viewing area compared with 
2.0 ± 0.7 in the collagen implant group. The differ-
ence was considered significant (P < 0.05) (Table 4). 
In the collagen group, the intrascleral space was 
lined with spindle cells. In the PMMA group, the 
X-shaped device was well identified and lined up 
with a higher number of spindle cells. 
No evidence of intlammatory reaction on the sur-
gical site was seen for either implant type. 
DISCUSSION 
The X-shaped implant made of synthetic non-
absorbable PMMA was designed to enhance the 
intrascleral outtlow. Being non-absorbable with 
good biocompatibility, the implant's role is to main-
tain a permanent patent intrascleral lake and prevent 
adhesions between the superficial scleral tlap and 
the trabecular meshwork, leading to a better IOP 
control. The implant is also supposed to stabilize and 
provide additional support to the thin TDM. Free 
areas between the limbs of the X-shaped implant 
should also act as an aqueous reservoir. The collagen 
implant has been the primary implant used in DS 
surgery. Its advantages are complete resorption, 
leaving a large subconjunctival bleb. It is made of 
porcine collagen and carries a potential risk of 
animal transmitted disease. 
During the entire follow up, the IOP-lowering 
effect of the DS with PMMA implant was similar to 
DS with a collagen implant. The maximal lowering 
effect was observed shortly after surgery and during 
the first postoperative 3 months for both groups. 
The fact that IOP was lowered to the san1e extent 
in both groups throughout the 6-month period 
indicates that the efficacy of DS in reducing the IOP 
with either implant is comparable. This was also 
confinned with the outtlow facility results showing 
a significant and equivalent increase for both types 
of implant. 
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Figure 3. Anterior segment angiographies: (a) preoperative; (b) X-shaped implant (i) and new vessels at 6 months post surgery; (c) 
X-shaped implant and subconjunctival filtration bleb (se) in late phase. 
Table 3. Angiography 
Mean number of new 1 months 3 months 6 months 
outflow vessels 
Collagen implant 0.8 ± 0.6 1.9±1.7 2.8 ± 1.4 
Polymethylmethacrylate 1.3 ± 0.5 2.6±1.1 3.1±1.1 
implant 
Wilcoxon rank sum test (P) 0.36 0.25 0.29 
Mean number of new subconjunctival outflow vessels over 
time. 
Table 4. Histology 
6 months Mean number of new 
outflow vessels Collagen implant PMMA implant 
Surgical site 
180° unoperated site 
Absolute new vessels 
Wilcoxon rank sum test (P) 
3.6 ± 0.7 5.1 ± 0.8 
1.6 ± 0.5 1.4 ± 0.5 
2.0 ± 0.7 3.7 ± 0.8 
p < 0.05 
Mean number of new scierai outflow vessels at 6 months. 
PMMA, polymethylmethacrylate. 
Anterior segment angiography images allowed an 
easy visualization of the subconjunctival aqueous 
draining pathway. Proliferation of new drainage 
vessels was observed around the operated tissues 
with both implant types. The subconjunctival prolif-
eration rate, as well as the IOP-lowering effect, were 
more important during the first 3 months, and there 
was no significant difference between the groups 
during the entire follow up. This would support the 
role played by such vessels in draining aqueous and 
a 
ib 
b 
oc 
Figure 4. Light microscopy of the operated site (a) and (b): 
anterior chamber (a), ciliary body (cb), corne a (c), conjunctiva (cj), 
X-shaped implant (i), intrascleral bleb (ib), outflow vessels (oc) 
and sciera (s). 
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controlling the IOP level. It is worth mentioning that 
the number of scleral drainage vessels, as observed 
on histological sections at 6 months, was more sig-
nificant in the PMMA group. This finding suggests 
that the PMMA device may potentially trigger a 
longer vasoproliferative response than the collagen 
implant. This could be explained by the permanent 
presence of the device compared with the degraded 
short-life collagen. 
In both groups, subconjunctival and intrascleral 
filtration blebs were equally identified on UBM in 
all eyes. However, the slower reduction in the 
height of the subconjunctival bleb observed in the 
collagen implant group may indicate a slightly 
more developed filtering bleb than in the PMMA 
group. We also observed the presence of choroidal 
effusion in half of the PMMA eyes and less than a 
third in collagen eyes. These observations may 
support the hypothesis that the aqueous outflow 
draining into the suprachoroidal space through a 
surgically thinned sclera might be higher in the 
PMMA group. For reasons that remain to be clari-
fied, this phenomenon was not associated with a 
significantly lower IOP, possibly as a consequence 
of a slight increase in the aqueous production coun-
terbalancing the higher outflow. Based on histology, 
the PMMA device was as well tolerated as the col-
lagen device and no severe inflammatory reactions 
were observed on the surgical site. However, 
the number of spindle cells lining on the scleral 
filtration space and fibrosis around the surgical site 
was more significant in the PMMA group. It is pos-
sible that the long-tenn effect of having an inert 
material may lead to a foreign body reaction trig-
gering a mild and locally marked scarring 
and tissue remodelling response. One observable 
difference was noted in the PMMA group: an 
increase in the intrascleral outflow with a shallower 
subconjunctival bleb was observed in the PMMA 
group. 
In this in vivo study, we demonstrated in through a 
rabbit model that the implant is well tolerated. A 
possible limitation of the present study might be 
unknown factors that led to a low IOP-lowering 
response (about 1.5 points or 10% in either surgery) 
in the rabbits' eyes. However, one explanation 
would be that these eyes did not profit from the same 
postoperative management (i.e. Nd:YAG gonioponc-
ture for fibrosis of the TDM, etc.) as human eyes. A 
randomized controlled trial comparing the same two 
implants in 60 human eyes showed a similar safety 
profile and a good success rate in both groups (42% 
of PMMA patients and 44% of collagen patients 
achieved an IOP of 21 mmHg or less without 
medication). 5 
In conclusion, the non-absorbable X-shaped 
PMMA implant compares favourably to the collagen 
© 2010 The Authors 
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implant in a rab bit model. The presence of new intras-
cleral drainage vessels and the onset of suprachoroi-
dal effusion support the concept that the intrascleral 
bleb filtration is one of the main outflow mechanisms 
for the PMMA implant. The PMMA implant might be 
a good and more affordable alternative to the standard 
collagen implant in decreasing the complications and 
discomfort related to large subconjunctival blebs. The 
use of the PMMA implant on a larger scale could also 
contribute to lower the potential risks related to the 
use of porcine collagen in terms of transmitting 
animal-carried diseases. 
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